Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Feb 24, 2006 by Edgar Snyder

Tysabri Up for FDA Debate

Tysabri

The Food and Drug Administration (FDA) faces a tough decision: Should the promising multiple sclerosis (MS) drug, Tysabri, be FDA approved again after being pulled from the market for potentially deadly side effects?

In 2004, Tysabri was withdrawn from the market by the FDA after its use was linked to a rare but fatal brain infection, progressive multifocal leukoencephalopathy (PMI). Since Tysabri shows such powerful effectiveness in treating MS, Biogen Idec Inc. and Elan Corp., makers of the drug, hope to convince the FDA to allow the drug to be put back on the market. Lotronex, a treatment for irritable bowel syndrome, is the only drug the FDA has allowed back on the market after a recall.

Previous studies have shown Tysabri reduced the rate of MS relapses by 66%. The drug also has a strong backing from MS patients who are willing to take the chance in order to ease their MS symptoms.

For more information about dangerous or recalled drugs, visit our Dangerous and Recalled Drugs Legal Center.

Drug litigation may involve co-counsel.

Source: “Tricky FDA Debate: Should a Risky Drug Be Approved Again.” By Anna Wilde Mathews and Sylvia Pagan Westphal. The Wall Street Journal. February 24, 2006.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Sep 16, 2016
New CDC Tool Will Help Keep Traveling Workers Safe
Tweet